Table 1.
Neoadjuvant chemotherapy regimen.
| Treatment programs | Composition | Concentration in vitro | Dose in vivo |
|---|---|---|---|
| TCb-HP | Docetaxel | 0, 0.001, 0.01, 0.1, 1, 10 μM | 75 mg/m2 |
| Carboplatin | 0, 0.001, 0.01, 0.1, 1, 2, 4, 8, 16, 32 μM | AUC6 | |
| Trastuzumab | – | The first dose is 8 mg/kg, then 6 mg/kg | |
| Pertuzumab | – | The first dose is 840 mg, then 460 mg | |
| THP | Docetaxel | 0, 0.001, 0.01, 0.1, 1, 10 μM | 75 mg/m2 |
| Trastuzumab | – | The first dose is 8 mg/kg, then 6 mg/kg | |
| Pertuzumab | – | The first dose is 840 mg, then 460 mg | |
| TCbH | Docetaxel | 0, 0.001, 0.01, 0.1, 1, 10 μM | 75 mg/m2 |
| Carboplatin | 0, 0.001, 0.01, 0.1, 1, 2, 4, 8, 16, 32 μM | AUC6 | |
| Trastuzumab | – | The first dose is 8 mg/kg, then 6 mg/kg | |
| TAC | Docetaxel | 0, 0.001, 0.01, 0.1, 1, 10 μM | 75 mg/m2 |
| Anthracyclines | 0, 0.001, 0.01, 0.1, 1, 2, 4, 8, 16, 32 μM | 50–100 mg/m2 | |
| Cyclophosphamide | – | 600 mg/m2 |
Note: The chemotherapy regimen for breast cancer patients requiring neoadjuvant chemotherapy in the First Affiliated Hospital of Chongqing Medical University. And the drugs used in the in vitro experiments with their concentrations.